Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMichael SladeFKFrank KuhrPTPaola Tononi

Discussion

Loading...

Member takes

Overview

Prospective cohort study shows circulating myeloma cells as a biomarker for response in CAR T cell therapy patients, indicating treatment success.

Key Points

  • This research examines the kinetics of circulating multiple myeloma cells (CMMCs) as a biomarker during anti-BCMA CAR T cell therapy.
  • Prospective cohort study of patients receiving anti-BCMA CAR T cell therapy.
  • Samples collected at various time points using the CellSearch system.
  • Analysis included next-generation sequencing (NGS) for mutation detection and cytogenetic changes.
  • At day +100, the overall response rate was 97%, with 62% achieving complete response.
  • Circulating multiple myeloma cells were detected in most patients post-infusion.
  • CMMC NGS identified 11/12 cytogenetic changes compared to standard FISH testing, revealing actionable mutations.

Cite This Study

Slade et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d16fhttps://doi.org/10.1182/blood-2025-5851
View Full Paper
Ask AI
Bookmark
Share